Other abnormal glucose
Methodology & AI Transparency ⓘ
Other abnormal glucose Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Clinical triage of Other abnormal glucose (R73.09) in Diabetes & Glucose relies on urine microalbumin-to-creatinine ratios [Other abnormal glucose R73.09], guiding step-wise therapeutic adjustments toward Fasting Insulin [Other abnormal glucose R73.09] (3.0 – 7.0 uIU/mL (R73.09)).
- 2 Real-world patient consensus: Diagnostic registry R73.09: Other abnormal glucose is managed within Diabetes & Glucose.
- 3 Typical cash cost range: Differential triage of Other abnormal glucose (R73.09) utilizes urine microalbumin-to-creatinine ratios [Other abnormal glucose R73.09].
- 4 Top reported side effects / signs: Objective lab/clinical target for Other abnormal glucose: Fasting Plasma Glucose [Other abnormal glucose R73.09] (75 – 95 mg/dL (R73.09)) and Fasting Insulin [Other abnormal glucose R73.09].
Ask our AI Specialists anything about Other abnormal glucose
What Is Other abnormal glucose?
Clinical triage of Other abnormal glucose (R73.09) in Diabetes & Glucose relies on urine microalbumin-to-creatinine ratios [Other abnormal glucose R73.09], guiding step-wise therapeutic adjustments toward Fasting Insulin [Other abnormal glucose R73.09] (3.0 – 7.0 uIU/mL (R73.09)).
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Other abnormal glucose (ICD-10 R73.09) is driven by advanced glycation end-product in Other abnormal glucose (R73.09: microvascular injury); specialists in Type 1 & Type 2 Diabetes monitor Fasting Insulin [Other abnormal glucose R73.09] to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Presentation of Other abnormal glucose (R73.09): blurred vision fluctuations in Other abnormal glucose (R73.09: or slower healing)
- • Secondary Other abnormal glucose clinical sign: elevated fasting blood in Other abnormal glucose (R73.09: glucose or post-meal)
- • Symptom flares in Other abnormal glucose correlating with Fasting Plasma Glucose [Other abnormal glucose R73.09] deviation outside 75 – 95 mg/dL (R73.09)
- • Functional diabetes & glucose impact requiring urine microalbumin-to-creatinine ratios [Other abnormal glucose R73.09] evaluation (R73.09)
Other abnormal glucose Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | R73.09 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Type 1 & Type 2 Diabetes | NLM Clinical Tables |
| Diagnostic / Lab Marker: Fasting Plasma Glucose [Other abnormal glucose R73.09] | 75 – 95 mg/dL (R73.09) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Insulin [Other abnormal glucose R73.09] | 3.0 – 7.0 uIU/mL (R73.09) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: CGM Time-in-Range (70–140 in Other abnormal glucose (R73.09: mg/dL)) | > 85% (R73.09) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Other abnormal glucose
Treatment selection for Other abnormal glucose depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Other abnormal glucose)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Valsartan vs. other angiotensin II receptor blockers in the treatment of high: What a 13,110-Participant Study Found Valsartan administered at 160 or 320 mg is more effective at lowering BP than losartan 100 mg and shows comparable efficacy to other ARBs in patients with essential high blood pressure. International journal of clinical practice • 2009-05-15 • Meta-Analysis | N = 13,110 | 99/100 | PMID 19392925 ↗ |
| New Insights on Efficacy comparison of monotherapies and combination therapies for androgenetic: What a 3,133-Participant Study Found In recent years, combination therapies are showing significant promise as potential therapies. Dermatologic therapy • 2022-03-15 • Meta-Analysis | N = 3,133 | 99/100 | PMID 34897933 ↗ |
| New Insights on Combination Therapy in Androgenetic hair loss: A Network Meta-Analysis of: What a 3,012-Participant Study Found Based on the current studies, we found that the combination of Minoxidil with spironolactone, PRPF, flutamide, and finasteride may offer better treatment outcomes for patients with androgenetic hair loss. Aesthetic plastic surgery • 2026-07-15 • Meta-Analysis | N = 3,012 | 99/100 | PMID 42168420 ↗ |
| New Insights on Safety profile of telmisartan as single-drug treatment or combined with: What a 8,023-Participant Study Found The consolidated data show that telmisartan +/- HCTZ are well tolerated in patients of all ages and have placebo-like tolerabilities. Blood pressure. Supplement • 2008-06-15 • Randomized Controlled Trial | N = 8,023 | 96/100 | PMID 18705533 ↗ |
| New Insights on Telmisartan and amlodipine single-pill combinations vs amlodipine single-drug: What a 1,097-Participant Study Found Superior BP reductions were also seen with T40-T80/A5 vs A10, with BP goal rates at least as high as with A10; however, there was significantly more peripheral edema with A10 (27.2% vs 4.3% for pooled. Journal of clinical hypertension (Greenwich, Conn.) • 2011-07-15 • Randomized Controlled Trial | N = 1,097 | 96/100 | PMID 21762357 ↗ |
Other abnormal glucose Patient Community & “People Like Me” Threads
Filter Other abnormal glucose community threads and patient logs by age, biological sex, dosage, and treatment duration.